treatment

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Original Publication Date
Article Source
External Web Content
Key Points Treg-engineered donor graft prevents acute and chronic GVHD. Patients treated with Treg-engineered graft who develop GVHD respond to primary corticosteroid therapy at a high rate. Abstract Allogeneic hematopoietic cell transplantation is a curative therapy limited by…

The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT

Original Publication Date
Article Source
External Web Content
Abstract The role of ABO blood group system mismatch on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes is controversial since current publications of large datasets are lacking. We retrospectively analyzed 30,487 patients transplanted between 2010 and 2021…

Ross L. Levine, MD

Institution
Memorial Sloan-Kettering Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)

Hawk Kim, MD, PhD

Institution
Gachon University Gil Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)

Rick J Jones, MD

Institution
Johns Hopkins University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Subscribe to treatment

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.